{
    "clinical_study": {
        "@rank": "141458", 
        "brief_summary": {
            "textblock": "To determine whether zidovudine (AZT) in conjunction with bone marrow transplantation\n      prevents the reinfection of donor hematopoietic/lymphoid cells in patients with positive\n      HTLV III antibody and large cell/diffuse histiocytic lymphoma. Patients who are candidates\n      will be evaluated for HTLV III activity and drug levels."
        }, 
        "brief_title": "A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant", 
        "condition": [
            "Lymphoma, Non-Hodgkin", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with current life-threatening infection at time of transplant that would preclude\n        a transplant are excluded.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Other anti-retroviral agents.\n\n        Patients with current life-threatening infection at time of transplant that would preclude\n        a transplant are excluded.\n\n        Patients must be:\n\n          -  HTLV III antibody positive by ELISA or Western blot or HTLV III viremia.\n\n          -  At high mortal risk with a diagnosis of AIDS or AIDS Related Complex (ARC).\n\n          -  Also patient must fall into one of the following categories:\n\n          -  Have an HIV seronegative identical twin to serve as a bone marrow donor.\n\n          -  Have documentation of large cell/diffuse histiocytic lymphoma/DPDL.\n\n          -  Be a good risk candidate for bone marrow transplant."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "12 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002284", 
            "org_study_id": "014A", 
            "secondary_id": "006"
        }, 
        "intervention": {
            "intervention_name": "Zidovudine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Zidovudine"
        }, 
        "keyword": [
            "Lymphoma, Large-Cell", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Zidovudine", 
            "Bone Marrow Transplantation"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21205"
                }, 
                "name": "Johns Hopkins Hemapheresis Treatment Ctr"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Pilot Study To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients Receiving a Bone Marrow Transplant", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002284"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glaxo Wellcome", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 1995"
    }, 
    "geocoordinates": {
        "Johns Hopkins Hemapheresis Treatment Ctr": "39.29 -76.612"
    }
}